Dr. Shaun Desai[/caption]
Shaun C. Desai, MD
Assistant Professor
Facial Plastic and Reconstructive Surgery
Department of Otolaryngology - Head & Neck Surgery
Johns Hopkins University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Desai: Estimates of the rate of revision septorhinoplasty and the risk factors associated with revision are unknown because the current published literature is limited to small, retrospective, single-surgeon studies with limited follow-up time. The purpose of this study is to determine the overall revision rates of patients undergoing a septorhinoplasty procedure (for functional or cosmetic reasons) and to determine risk factors for the revision. We found that the overall revision rate was 3.3% (5,775 patients of a total of 175,842 patients undergoing the procedure) with an average time to revision at 1 year. Risk factors for revision surgery included female gender, younger age, a history of anxiety or autoimmune disease, cosmetic indications, and more complicated initial surgery (i.e. cleft rhinoplasty).
Dr. Carr[/caption]
MedicalResearch.com Interview with:
Tara F Carr, MD
Assistant Professor, Medicine and Otolaryngology
Allergy and Immunology Fellowship Training Program Director
Director, Adult Allergy
Division of Pulmonary, Allergy, Critical Care and Sleep Medicine
University of Arizona
Tucson, AZ 85724
Medical Research: What is the background for this study? What are the main findings?
Dr. Carr: Some patients with chronic rhinosinusitis continue to suffer from symptoms despite aggressive medical and surgical treatments. For these individuals, therapy is generally chosen based on bacterial culture results, and often includes the use of topical antibacterial rinses with a medication called mupirocin. We found that if patients are still having problems after this treatment, the bacteria identified from repeated sinus cultures are very different than those usually expected, and in general more difficult to treat.
MedicalResearch.com Interview with:
Nishant Agrawal M.D.
Associate Professor of Otolaryngology
Johns Hopkins University School of Medicine
Medical Research: What is the background for this study? What are the main findings?
Dr. Agrawal: The idea of the study really arose from the specificity of genetic changes that characterize and are the hallmark of cancer cells. Only cancer cells contain these mutations so their detection in bodily fluids was a reasonable expectation. The current study builds on previous work from our group that tumor DNA can be detected in the bodily fluids of patients with many different types of solid malignancies. The main findings of the study are that tumor DNA in saliva and plasma provides a non-invasive biomarker for head and neck cancer. The take home message is that tumor DNA has potential to be used as a biomarker for screening, early detection, monitoring during treatment, and surveillance after cancer treatment is completed.